Desferrioxamine-metal complexes for the treatment of immune-related disorders

A kit for achieving a therapeutic effect in a subject in need thereof comprising at least one of:

• (I) compounds for Zn-DFO complex formation comprising:
• (i) Zinc ions (Zn(II)) in any form of salts, esters and amides thereof, or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier or diluent, optionally, in a first unit dosage form;
• (ii) DFO, or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier or diluent, optionally, in a second unit dosage form;
• and
• (iii) optionally solutions, buffers and components which provide suitable conditions for complex formation;
• (II) compounds for Ga-DFO complex formation comprising:
• (i) Gallium ions (Ga(III)) in any form of salts, esters and amides thereof, or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier or diluent, optionally, in a third unit dosage form;
• (ii) DFO, or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier or diluent, optionally, in a fourth unit dosage form;
• and
• (iii) optionally solutions, buffers and components which provide suitable conditions for complex formation;
• (III) compounds for Mn-DFO complex formation comprising:
• (i) Manganese ions, in any valecy state, including but not limited to Mn(II), Mn(III) and Mn(IV), in any form of salts, esters and amides thereof, or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier or diluent, optionally, in a fifth unit dosage form;
• (ii) DFO, or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier or diluent, optionally, in a sixth unit dosage form;
• and
• (iii) optionally solutions, buffers and components which provide suitable conditions for complex formation;
• (IV) container means for containing said unit dosage forms.